EDUCATION

Biological studies:

November 1980:
Degree in Biological Sciences. University (Università degli Studi) of Milan (Italy)

November 1986:
PhD in Biochemistry and Clinical Chemistry.
University of Milan.

QUALIFICATION FOR DENTAL OFFICE

September-December 1993:
Training in dental nursing and dental hygiene.

June 1994:
Training in dental nursing specialized in implantology.

1994-2008:
Training in parodontal microbiology, disinfection/sterilization procedures

PROFESSIONAL ACTIVITIES

Biological Research:

1978-1980:
Internal Student, Dept Chemistry and Biochemistry. University of Milan.

1980-1983:
Collaborator, Dept. Chemistry and Biochemistry. University of Milan. (P.I. Prof. B. Cestaro). Research field: physical-chemical properties of model membranes (red blood cell ghosts, liposome).

October 1983-Dicember 1986:
Grant from S. Raffaele Scientific Institute, Milan- Italy, Clinical chemistry laboratory (P.I. Prof. PA Bonini). Research field: pH differential technique, analysis on whole blood.

1987-1992:
Grant from Rivetti Foundation (Milan, Turin- Italy). Biochemistry and molecular Biology laboratory (P.I. Prof. C. Vergani). Research field: lipoproteins, oxidized lipoproteins, quality controls of clinical chemistry analysis, atherosclerosis risk factors.

From November 1992:
Collaborator, CNR-ISTM Istituto di Scienze e Tecnologie Molecolari, (P.I. Silvia Bradamante). NMRONE Laboratory (Università Bicocca-Via dell’Innovazione 10-20125 Milan). Research field: Oxidative modifications/damages by free radicals on biological models (ex-vivo hearts, cell cultures, lipoproteins) in physio-pathological conditions (ischemic preconditioning, cardiovascular deconditioning, and atherosclerosis). In the last years, the research has been focused on gravity-dependent modulations in the proliferation and differentiation of different cells (Unsworth B.R.et al., 1998) in particular of endothelial cells, lymphocytes and yeast. Our aim is to exploit the advantages of modelled microgravity in the field of some ground biotechnological applications of industrial relevance (autologous stem-cell therapy, tissue engineering, increased productivity of pharmaceutical products) (Bradamante S. 2005).

The reported research allowed publishing scientific papers and abstracts.

WORK IN DENTAL OFFICE AND TEACHING

November 1992- June '93:
organization/office administration in private dental offices

From 2007:
speaker in courses and workshop on procedures of disinfection and sterilization for dental offices according the EC directives and national and regional Italian rules .

RESEARCH ACTIVITY

The research points to oxidative modifications/damages caused by free radicals on biological models (ex-vivo hearts, cell cultures, lipoproteins) in physio-pathological conditions (ischemic preconditioning, cardiovascular deconditioning, and atherosclerosis). In the last years, the research has been focused on gravity-dependent modulations in the proliferation and differentiation of different cells (Unsworth B.R.et al., 1998) in particular of endothelial cells, lymphocytes and yeast. Our aim is to exploit the advantages of modelled microgravity in the field of some ground biotechnological applications of industrial relevance (autologous stem-cell therapy, tissue engineering, increased productivity of pharmaceutical products) (Bradamante S. 2005).

Are these researches of interest in dental practice?

1.
A lot of dental procedures utilize products (chemical compounds) that cause an oxidative stress, for example:
• tooth bleaching;
• disinfection/sterilization with peroxygens;
• disinfection of dental unit water system.

2.
Environmental microbial contamination is a common risk in space station and dental office. Both systems have structural features (small dimension, limited air exchange and complex and miniaturized instrumentation) that favour this condition. Alterations in the virulence potential and increased bacterial resistance have been reported in simulated microgravity. Many serious adverse physiological changes occur during spaceflight. Some of these include bone deterioration, cardiovascular deconditioning and impaired immune system function. Mainly, host immune mechanism impairment and increased bacterial pathogenesis might results in severe infections during long-term human exploration of space. Microbial monitoring and disinfection abroad spacecraft is becoming increasingly important.

3.
Nowadays, there is a big demand for the development of construct technologies aimed at producing and characterizing 3D cell devices (artificial tissue, organoids..) to be used in health care and pharmaceutical industry (Martin I et al., 2004). Microgravity is becoming an unconventional and attractive venue for the generation of replacement organs for transplantation. Microgravity favours tissue formation by mainly preventing structural deformation and favouring 3D assembly. Future studies of modelled microgravity in this field will advantage some ground biotechnological applications of industrial relevance (autologous stem-cell therapy, tissue engineering, increased productivity of pharmaceutical products).

PUBLICATIONS

1. Measurement of transmembrane proton diffusion through lecithin vesicles containing glycolipids. Cestaro B, Cervato G, Barenghi L, Pistolesi E. Biochemistry International 5,1,145-150 (1982)

2. Fusion of sulphatide-containing vesiclesof phosphatidylcoline. Cestaro B, Cervato G, Barenghi L et al. European Journal Biochemistry 133,229-233 (1983)

3. Principi di pHmetria differenziale e sue applicazioni in chimica clinica. Ceriotti F, Barenghi L, Bonini PA et al. Giornale Italiani Chimica Clinica 9,2,93-106 (1984)

4. Measurement of lipase activity by a differential pH technique. Ceriotti F, Bonini PA, Murone M, Barenghi L et al. Clinical Chemistry 31,2,257-260 (1985)

5. Optimization of urinary acid alpha-glucosidase determination. Ceriotti F, Barenghi L, Pontillo M et al. Journal Clinical Chemistry Clinical Biochemistry 23,845-850 (1985)

6. Measurement of erythrocyte acetylcholinesterase and plasma cholinesterase activity by a differential pH technique. Barenghi L, Ceriotti F, Luzzana M, Ripamonti M, Mosca A, and Bonini PA. Annals Clinical Biochemistry 23, 538-545 (1986)

7. Effects of suprofen on renal function in patients with rheumatoid arthritis. Malandrinoi S, Angelini M, Baldini L, Barenghi L et al. Int J Clin pharmacol Res. 7, 4, 259-263 (1987)

8. Eritrocytic Glucose-6-phosphate Dehydrogenase measured by a Differential pH Technique. Barenghi L, Ceriotti F, Ripamonti M, Luzzana M, Bovini P.A. Clinical Chemistry 33, 579-582 (1987)

9. An alternative expeditious analysis of phospholipid composition in human blood plasma by P-31 NMR spectroscopy. Bradamante S, Barchiesi E, Barenghi L, Zoppi F. Analytical Biochemistry 185, 299-303 (1990).

10. NMR analysis of low-density lipoprotein oxidatively-modified in vitro. Barenghi L, Bradamante S, Giudici GA, Vergani C. Free Radical Research Communications8, 3, 175-183 (1990).

11. Human apolipoprotein A-1 gene promoter polymorphism: association with hyperalphalipoproteinemia. Pagani F, Sidoli S, Giudici GA, Barenghi L et al. Journal of Lipid Research, 31,1371-1377 (1990).

12. Evidenze di modificazioni delle LDL indotte da reazioni radicaliche in vivo e in vitro. Barenghi L, Bradamante S, Giudici GA,Vergani C. Atti del XXII congresso nazionale della Societa' italiana per lo studio del metabolismo normale e patologico. Bompiani GD e Galluzzo A ed. Palermo 17-18 novembre 1989. Edizioni Minerva Medica, TO pag. 121-129 (1990).

13. Free radicals promote modifications on plasma high-density lipoprotein: NMR analysis. Bradamante S, Barenghi L, Giudici G, Vergani C. Free Radical Biology and Medicine 12, 193-203 (1992)

14. Cardiovascular risk factors in 4073 working people in Northern Italy (The Rivetti Heart Study, 1987-1990). Giudici GA, Barenghi L, Persico D, Gallus G, Milani S, Lavezzaro GC, Vergani C. Cardiovascular Risk Factors, 2, supplemento 1, 1-46, (1992).

15. The protective role of HDL on oxidized-LDL-induced U937/endothelial cell interactions. Majer J.A., Barenghi L., Pagani F., Bradamante S., Comi P., Ragnotti G. European Journal of Biochemistry 221, 35-41 (1994)

16. Modulators of oxidized LDL-induced hyperahesiveness in human endothelial cells. Maier J.A.,Barenghi L., Bradamante S., Pagani F. Biochemical Biophysical Research Communications 204, 2, 673-677 (1994)

17. Induction of human endothelial cell growth by oxidized low density lipoproteins. Majer J.A., Barenghi L., Bradamante S., Pagani F. Atherosclerosis 123,1-2,115-121 (1996)

18. Does resveratrol induce pharmacological preconditioning? Bradamante S, Piccinini F, Barenghi L, Bertelli AA, De Jonge R, et al. Int J Tissue React 22,1,1-4 (2000)

19. Glycogen turnover and anaplerosis in preconditioned rat hearts. Bradamante S, Marchesani A, Barenghi L et al. Biochim Biophys Acta 1502,3,363-379 (2000)

20. Production of lovastatin examined by an integrated approach based on chemometrics and DOSY-NMR. Bradamante S, Barenghi L, Beretta G et al. Biothecnol Bioeng 80,5,589-593 (2002)

21. Resveratrol provides late-phase cardioprotection bt means of a nitric oxide- and adenosine-mediated mechanism. Bradamante S, Barenghi L, Piccinini F,Bertelli AA, De Jonge R, et al. Eup J Pharmacol 465,1-2,115-123 (2003)

22. Bioreactore, in particulare per spettroscopia NMR. Bradamante S, Barenghi L, Villa A. PD2003A00142 (2003)

23. A NMR-compatible and reduced gravity simulation based (NRG) bioreactor for on-line monitoring cell culture metabolism. Bradamante S, Barenghi L, Villa A. J Gravit Physiol 11,2, 191-192 (2004)

24. Simulated weightlessness in the design and exploitation of a NMR-compatible bioreactor. Bradamante S, Barenghi L, Villa A. Biotechnol prog 20,5,1454-1459 (2004)

25. Cardiovascular Protective effects of resveratrol. Bradamante S, Barenghi L, Villa A. Cardiovascular Drug Reviews 22,3,169-188 (2004)

26. Bioreactor, in particular for NMR spectroscopy. Bradamante S, Barenghi L, Villa A. Eur Pat 2005, EP1500944 (2005)

27. Effects of space-flight simulation on human cells. Villa A, Versari S, Barenghi L Maier JAM, Bradamante S. Journal of Gravitational Physiology 2005

28. Advantages of simulated microgravity in the production of compounds of industrial relevance.Versari S, Villa A, Barenghi L, Bradamante S. Journal of Gravitational Physiology 2005

29. From hypergravity to microgravity: choosing the suitable simulator.
Bradamante S, Barenghi L, Versari S, Villa A. Microgravity Sci.Ttechnol. XVIII-3/4, 250-253 (2006)

30. Does caffeine affect cardiovascular responses? Bradamante S, Barenghi L, De Jong JW et al. Vascular Disease Prevention (2006) in press

ABSTRACTS

1. Membrane fusion trough point defects in phospholipid bilayers containing brain sulphatide. Cestaro B, Cervato G, Barenghi L, Pistolesi E. Basic and Clinical Aspects of Molecular Neurobiology. ESN. Fond. Menarini 1982

2. Studio in membrane modello dell'attivita' del trasportatore del D-glucosio da eritrociti di pazienti diabetici. Cestaro B, Cervato G, Barenghi L et al. 29 Congresso Nazionale della Societa' Italiana di Biochimica, 26-28th september 1983 Saint Vincent pag 361.

3. Determinazione della colinesterasi sierica ed erithrocitaria mediante pHmetria differenziale. Ceriotti F, Barenghi L, Luzzana M et al. SiBioC, Congresso di Lacco Ameno D'Ischia 11-14/10/1984, 143-P3.19

4. Determination of serum and erythrocyte cholinesterase activity by differential pH measurement. Ceriotti F, Barenghi L, Luzzana M et al. XII International Congress of Clinical Chemistry Brazil 1984, n 2902

5. Valori di riferimento preliminari di alcuni enzimi tubulospecificie andamento in soggetti sottoposti a trapianto renale.Barenghi L, Fermo I, Ceriotti F, Bonini PA. SiBioC 1985. Biochim Clin 9, 1049, 1985

6. Differential pH measurements in clinical chemistry analysis. Mosca A, Ripamonti M, Luzzana M, Rossi Bernardi L, Barenghi L. SiBioC 1985. Biochim Clin 9, 1087, 1985

7. L-Lactate determination in blood by differential pH.Ripamonti M, Luzzana M, Marconi C, Barenghi L. SiBioC 1985. Biochim Clin 9, 1079, 1985

8. Confronto tra tre metodiche per il dosaggio della lipasi pancreatica.Barenghi L, Ceriotti F, Dorigatti F, Bonini PA. SiBioC 1985. Biochim Clin 9, 1018, 1985

9. Effect of Suprufen on renal function in patients with rheumatoid arthritis. Malandrino M, Angelini M, Baldini L, Barenghi L et al. II World Conference on Inflammation Antirheumatics, analgesic, immunomodulators, Monte Carlo 19-22/3/1986

10. Analisi chimico-cliniche su sangue intero. Metodologie analitiche e strumentazione. Bonini PA, Ceriotti F, Sanguini L, Mosca A, Barenghi L. XXXVI Congresso Nazionale AIPaC, Ancona 21-24/5/1986. pag 90.

11. Determinazione della G6PD eritrocitaria mediante pHmetria differenziale. Barenghi L, Ceriotti F, Ripamonti M, Luzzana M, Bonini PA. SIBioC 1986, Verona. pag 185.

12. Differential pH measurement to determine analytes in erythrocytes. Bonini PA, Ceriotti F, Barenghi L, Luzzana M, Mosca A, Ripamonti M. Clin Chem 33,9,1558-1559 (1987)

13. LDL oxidised in vitro: preliminary results obtained by NMR spectroscopy. Barenghi L, Bradamante S, Giudici G, Vergani C. Modified Lipoproteins - Satellite Meeting 8th International Symposium on Atherosclerosis. Venice, October 7-8,1988- pag 29-34

14. Effect of simvastatin on total and lipoprotein lipids, apoproteins and plasma vitamin E in heterozygous familial hypercholesterolemia. Giudici G, Stefanoni S, Chuchel M, Cerri M, Clerici MG, Barenghi L, Pagani F, Vergani C. 8th International Symposium on Atherosclerosis. Rome, October 9-13,1988- pag 303

15. Preliminary results of a prospective epidemiological study in a working population in the Turin area (The Rivetti Heart Study). Giudici G, Barenghi L, Clerici MG, Pagani F, Checchinato C, Lavezzaro GC, Vergani C. RIA '89. Milan, May 8-10, 1989. pag 114

16. Low density lipoprotein oxidised in vitro: preliminary results obtained by nuclear magnetic resonance spectroscopy. Bradamante S, Barenghi L, Giudici G, Vergani C. 8th European Congress of Clinical Chemistry. Milan , June 25-30 1989. S 70

17. The NMR approach: diagnostic efficiency in the study of lipid peroxidation in cancer patients. Bradamante S, Lotzniker M, Pavesi F, Barenghi L, Vergani C. 6th International Conference on Human Tumor Markers. May 23-26 1989 Tokyo.

18. Oxidative modifications of LDL: evidences of a free radical mediated process in vitro and in vivo. Barenghi L, Bradamante S, Giudici G, Vergani C. 7th International Meeting Atherosclerosis and Cardiovascular Disease. Bologna 25-27 september 1989. 128C

19. Prevalence of dyslipidemia in the Rivetti Heart Study: preliminary results. Giudici G, Barenghi L, Clerici MG, Pagani F et al. 7th International Meeting Atherosclerosis and Cardiovascular Disease. Bologna 25-27 september 1989. 70C

20. Association of a polymorphism in the apo-A1 gene promoter with hyperalphalipoproteinemia. Pagani F, Sidoli A, Barenghi L, Giudici G et al. 7th International Meeting Atherosclerosis and Cardiovascular Disease. Bologna 25-27 september 1989. 43.

21. Evidenze di modificazioni delle LDL indotte da reazioni radicaliche in vitro ed in vivo. Barenghi L, Bradamante S, Giudici G, Vergani C. XXII Congresso Nazionale della Societa' Italiana per lo Studio del Metabolismo Normale e Patologico. I radicali Liberi in Fisiologia e Patologia. Palermo 17-18 novembre 1989. (comunicazione orale)

22. Prevalence of hypoalphalipoproteinemia in the Rivetti Heart Study. Preliminary results. Guidici GA, Barenghi L, Clerici MG, Merati G et al. 55th Meeting of the European Atherosclerosis Society. Brugge- May 16-19,1990. 226

23. Oxidatively modified LDL: identification of oxygenated derivatives produced by a free radical mediated process. Barenghi L, Bradamante S, Giudici G, Vergani C. 55th Meeting of the European Atherosclerosis Society. Brugge- May 16-19, 1990. 111.

24. Evidence for the presence of oxidatively modified LDL in human atheroslerotic lesions. Bradamante S,Barenghi L,Giudici G, Vergani C. XII Congress of the European Society of Cardiology. European Heart Journal 11,1990.P251.

25. Biochemical and NMR analysis of in vitro oxidized and MDA- treated HDL. Barenghi L, Bradamante S,Giudici GA, Vergani C. 56th European Atherosclerosis Society. Santa Maria di Pula,Cagliari.10-13 Ottobre 1990. 135.

26. A new italian case of familial lecithin:cholesterol acyltransferase (LCAT) deficiency. Giudici GA, Antonucci F, Barenghi L,Pizzolito S et al. 56th European Atherosclerosis Society. Santa Maria di Pula,Cagliari.10-13 Ottobre 1990. 196.

27. Prevalence of hypoalphalipoproteinemia in the Rivetti Heart Study. Giudici G, Barenghi L,Clerici M,Merati G, Pagani F et al. 56th European Atherosclerosis Society. Santa Maria di Pula,Cagliari.10-13 Ottobre 1990. 197.

28. NMR analysis of high-density lipoprotein oxidatively modified in vitro. Barenghi L, Giudici G, Vergani C and Bradamante S. 5th Biennal Meeting of the International Society for Free Radical Research. Pasadena 14-20 november 1990.Free Radical Biology and Medicine 9, 11,67 1990. 7.9.

29. Presence of oxidatively modified lipids in human atheroslerotic lesions. Bradamante S, Barenghi L, Giudici G,Capaldi G et al. 5th Biennal Meeting of the International Society for Free Radical Research. Pasadena 14-20 november 1990. Free Radical Biology and Medicine 9, 11,67 1990. 7.12.

30. NMR analysis of low-density lipoprotein oxidatively modified in vitro. Bradamante S, Barenghi L, Giudici G, Vergani C. 5th Biennal Meeting of the International Society for Free Radical Research. Pasadena 14-20 november 1990.Free Radical Biology and Medicine 9, 11,68 1990. 7.13.

31. The NMR approach to recognize human modified lipoproteins in vitro and in vivo. Bradamante S, Barenghi L, Giudici G, Vergani C. 5th Biennal Meeting of the International Society for Free Radical Research. Pasadena 14-20 november 1990. Free Radical Biology and Medicine 9, 11,68 1990. 7.14.

32. Lipoprotein lipid anomalies and lipid peroxidation in cancer patients. Bradamante S, Barenghi L. 5th Biennal Meeting of the International Society for Free Radical Research. Pasadena 14-20 november 1990.Free Radical Biology and Medicine 9, 11,68 1990. 18.10.

33. Modificazioni delle HDL3 indotte da radicali liberi in vitro. Barenghi L., Bradamante S., Vergani C. Atti del Simposio: I fattori di rischio della malattia cardiovascolare. Milano 22/11/1991. pag 59-66 (comunicazione orale)

34. Marked susceptibility to oxidation of HDL3 in vitro. Bradamante S, Barenghi L, Vergani C. Arteriosclerosis Council Abstract. Arteriosclerosis 11, 5, (1991) 1487a.

35. Free radicals promote modifications in HDL3 in vitro. Barenghi L, Bradamante S, Vergani C. XI International Symposium on Drugs affecting Lipid Metabolism. Florence, may 13-16 1992, Italy, pag 4 (comunicazione orale).

36. Mildly andextensively oxidized lipoprotein (LDL and HDL). Barenghi L, Bradamante S, Merati G, Vergani C. XI International Symposium on Drugs affecting Lipid Metabolism. Firenze, maggio 13-16 1992, pag 96

37. Lipoxygenase-catalyzed modifications on HDL3. Barenghi L, Bradamante S, Merati G, Vergani C. VI Biennal Meeting "Free Radicals: from basic science to medicine". Torino giugno 16-20 ,1992. Free Radical research Communications 16, supplemento 1, 1992, 18.9

38. The protective role of HDL on oxidized LDL effects in human endothelial cells. Bradamante S., Maier J.A., Barenghi L.. Lipoprotein oxidation and atherosclerosis. Biological and clinical aspects. Pavia 16-18 settembre 1994. Atti congresso. P9.

39. Exploitation of a NMR-compatible and reduced gravity simulation based (NRG) bioreactor. Bradamante S, Barenghi L, Versari S, Villa A. 20th Annual meeting of ASGSB - American Society for Gravitational and Space Biology New York, 9-13 Novembre 2004

40. A NMR-compatible and reduced gravity simulation based (NRG) bioreactor for the on-line monitoring of cell culture metabolism. Bradamante S, Barenghi L, Villa A. 25th Annual International Gravitational Physiology Meeting. Mosca 6-11 giugno 2004

41. Effects of space-flight simulation on human cells. Villa A, Versari S, Barenghi L, Maier JAM, Bradamante S. 26thAnnual International Gravitational Physiology Meeting and the 9th Tri-annual European Life Sciences, Cologne, Germany 26 June -1 July 2005.

42. Advantages of simulated microgravity in the production of compounds of industrial relevance.Versari S, Villa A, Barenghi L, Bradamante S. 26thAnnual International Gravitational Physiology Meeting and the 9th Tri-annual European Life Sciences, Cologne, Germany 26 June -1 July 2005.

43. From hypergravity to microgravity: choosing the suitable simulator. Bradamante S, BarenghiL, Versari S, Villa A. Bulletin of the European Low gravity research Association N°24. pag 292. ELGRA - Santorini (GR) 21-23 settembre 2005

POSTGRADUATE TRAINING LECTURE

1.Sterilizzazione e disinfezione: stato dell' arte, protocolli, e normative Europee per una sicurezza ad alto livello nello studio Odontoiatrico.
Relatori: Dr. A. Barenghi, Dr.ssa L. Barenghi
Lecco 2007.

2.Sterilizzazione e disinfezione: stato dell'arte, protocolli, e normative Europee per una sicurezza ad alto livello nello studio Odontoiatrico.
Relatori: Dr. A. Barenghi, Dr.ssa L. Barenghi
Lecco 2008.

3.Il processo di sterilizzazione & rischio infettivo in trattamenti odontoiatrici chirurgici e implantologici.
Relatori: Dr.ssa L. Barenghi
Lecco 2008.

4.Workshop “Luci (3M Attest 1292E) ed ombre nella sterilizzazione attuata in studi odontoiatrici.
Relatori: Dr.ssa L. Barenghi
3M e Dental Trey. Milano 2008.

5.“Sterilizzazione e disinfezione: stato dell'arte, protocolli, e normative Europee per una sicurezza ad alto livello
nello studio Odontoiatrico”.
Relatori: Dr.ssa L. Barenghi
I.O.S. Milano 2008

6.Workshop “L’importanza delle norme tecniche di sterilizzazione, partendo dalla Direttiva Europea 93/42”.
Relatori: Dr.ssa L. Barenghi
3M e Dental Trey. Torino 16/6/08.

7.Workshop “Il processo di sterilizzazione in ambito odontoiatrico: l’autoclave, norme e controlli”.
Relatori: Dr.ssa L. Barenghi
Dental Trey. Milano 2008.

8.Seminario “Stato dell’arte sulla Sterilizzazione
in Campo Odontoiatrico”. Ordine dei Medici ed Odontoiatri
Lecco.
Lecco 2008.

9.“Il processo di sterilizzazione & rischio infettivo in trattamenti odontoiatrici chirurgici e implantologici”.
I.O.S. Milano 2008.

10.Seminario “Stato dell’arte sulla sterilizzazione in campo odontoiatrico”. Ordine dei Medici ed Odontoiatri di Lecco. Lecco, 2008.

11.Seminario “Il processo di sterilizzazione in campo odontoiatrico alla luce della Direttiva Europea 93/42/EC”. ANDI Sondrio.
Sondrio 2009

12.Aggiornamento accreditato ECM “Il processo di sterilizzazione in odontoiatria” . ANDI MI-LO.
Milano 2009.

13.Aggiornamento accreditato ECM “Nuove tecnologie nel processo di sterilizzazione in odontoiatria”.
ANDI Como.
Como 2009.

14.Iniziativa formativa (coordinatrice Dr.ssa Sparaco A.) “Le cure odontoiatriche e infezione da HIV” con “Dalla teoria alla pratica per un processo efficiente  di sterilizzazione in odontoiatria”.
A.O. Luigi Sacco, Milano 2009/10.

15.Aggiornamento accreditato ECM “ Dal processo di sterilizzazione all’ergonomia dello strumentario chirurgico in odontoiatria: dai problemi di oggi alle prospettive future” .
Università La Sapienza. Dipartimento di Scienze Odontostomatologiche e Bontempi Chirurgische Instrumente.  Roma 2010.